{"filing":{"accession_number":"0001437749-26-020562","cik":"0001069530","ticker":"FLNA","company_name":"FILANA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"sava20260610_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/sava20260610_8k.htm"},"events":[{"id":10880,"run_id":9544,"accession_number":"0001437749-26-020562","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Filana Therapeutics held its 2026 Annual Meeting of Stockholders on June 11, 2026, with certified voting results on four proposals: election of three directors, amendment to the 2018 Omnibus Incentive Plan, ratification of Ernst \u0026 Young LLP as auditor, and an advisory vote on executive compensation.","company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7305,"accession_number":"0001437749-26-020562","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of Amendment No. 2 to the 2018 Omnibus Incentive Plan, which modifies compensatory arrangements for officers and directors by increasing authorized shares, extending the plan term, restricting repricing of equity awards, and adjusting compensation limits. This is a material amendment to the company's equity compensation framework affecting executive and director compensation arrangements.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T10:25:07.796624+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7306,"accession_number":"0001437749-26-020562","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 discloses the certified results of the 2026 Annual Meeting of Stockholders held on June 11, 2026, including voting outcomes on four proposals: election of three directors, amendment to the 2018 Omnibus Incentive Plan, ratification of Ernst \u0026 Young LLP as auditor, and advisory vote on executive compensation. The filing presents vote tallies (for, against, abstain, broker non-votes) for each matter, which is the core disclosure required under Item 5.07 for shareholder meeting results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T10:25:07.796624+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7305,"accession_number":"0001437749-26-020562","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of Amendment No. 2 to the 2018 Omnibus Incentive Plan, which modifies compensatory arrangements for officers and directors by increasing authorized shares, extending the plan term, restricting repricing of equity awards, and adjusting compensation limits. This is a material amendment to the company's equity compensation framework affecting executive and director compensation arrangements.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T10:25:07.796624+00:00","company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","filing_date":"2026-06-15"},{"id":7306,"accession_number":"0001437749-26-020562","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 discloses the certified results of the 2026 Annual Meeting of Stockholders held on June 11, 2026, including voting outcomes on four proposals: election of three directors, amendment to the 2018 Omnibus Incentive Plan, ratification of Ernst \u0026 Young LLP as auditor, and advisory vote on executive compensation. The filing presents vote tallies (for, against, abstain, broker non-votes) for each matter, which is the core disclosure required under Item 5.07 for shareholder meeting results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T10:25:07.796624+00:00","company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","filing_date":"2026-06-15"}]}